Paper1069608
Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia.
Wiernik PH and 6 others. Cancer Treat Rep, 1976. Cited by 89 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia. Papers, record 1069608. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1069608
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia.
- PubMed
- Publication types
- Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Leukemia | Major topic |
| Acute Disease | |
| Aged | |
| Bone Marrow | |
| Central Nervous System Diseases | |
| Cyclophosphamide | |
| Cytarabine | |
| Daunorubicin | |
| Drug Therapy, Combination | |
| Female | |
| Guanazole | |
| Humans | |
| Leukemia, Myeloid, Acute | |
| Male | |
| Meninges | |
| Middle Aged | |
| Pyrimethamine | |
| Remission, Spontaneous | |
| Skin Tests | |
| Thioguanine |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 89 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 34,068,720 | OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs. | Cells | 2021 | https://conductscience.org/library/papers/34068720 | PubMed |
| 27,517,413 | Acute myeloid leukaemia-A review of sixty-seven cases. | Ir J Med Sci | 1979 | https://conductscience.org/library/papers/27517413 | PubMed |
| 8,968,695 | A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy. | Drug Saf | 1996 | https://conductscience.org/library/papers/8968695 | PubMed |
| 7,347,042 | Remission-induction regimens in acute nonlymphocytic leukemia. | West J Med | 1980 | https://conductscience.org/library/papers/7347042 | PubMed |
| 6,961,971 | Uptake and metabolism of daunorubicin by human leukemia cells. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/6961971 | PubMed |
| 3,207,892 | Experiences with the Ommaya reservoir for prophylaxis and treatment of the central nervous system in adult acute myelocytic leukemia. | Blut | 1988 | https://conductscience.org/library/papers/3207892 | PubMed |
| 98,107 | Infection in acute leukemia patients receiving oral nonabsorable antibiotics. | Antimicrob Agents Chemother | 1978 | https://conductscience.org/library/papers/98107 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1069608
GET https://conductscience.org/api/papers/v1/1069608/authors